Is Eltrombopag/Eltrombopag a hormonal drug?

Eltrombopag/Eltrombopag is not a hormonal drug. Eltrombopag is a new oral anticoagulant drug that is a thrombopoietin receptor agonist. Its main function is to promote the growth of platelets. It reduces or prevents bleeding by stimulating the bone marrow to produce more platelets. Eltrombopag is mainly used to treat chronic immune thrombocytopenia, especially for patients who have poor response to treatments such as glucocorticoids and immunoglobulins, or who have relapsed after splenectomy.

The mechanism of action of Eltrombopag mainly includes anti-platelet aggregation, reducing blood viscosity, regulating coagulation function, etc. It can inhibit the concentration of ADP in the body, thereby inhibiting platelet aggregation and reducing the production of activated platelets. At the same time, Eltrombopag can also reduce blood lipid levels, such as low-density lipoprotein cholesterol, triglycerides, etc., as well as the adhesion rate of platelets, thereby reducing blood viscosity. In addition, Eltrombopag can also activate factors in the body, such as interleukin-4, tumor necrosis factor, etc., thereby regulating the coagulation function in the body.

There are a few things to note when using eltrombopag. It should be used with caution under the guidance of a doctor, especially for adolescents over 12 years old, the elderly, pregnant and lactating women, people with liver damage and kidney damage, and people at risk of thromboembolism. The dose of eltrombopag should be adjusted based on the patient's specific condition. For Orientals or patients with hepatic insufficiency, the general starting dose is 25 mg, once a day, and the effect is better when administered on an empty stomach. The storage of Eltrombopag also requires attention. It is generally stored in a refrigerator at 2℃-8℃, and the validity period is within 12 months.